Kavousi Maryam, Desai Chintan S, Ayers Colby, Blumenthal Roger S, Budoff Matthew J, Mahabadi Amir-Abbas, Ikram M Arfan, van der Lugt Aad, Hofman Albert, Erbel Raimund, Khera Amit, Geisel Marie H, Jöckel Karl-Heinz, Lehmann Nils, Hoffmann Udo, O'Donnell Christopher J, Massaro Joseph M, Liu Kiang, Möhlenkamp Stefan, Ning Hongyan, Franco Oscar H, Greenland Philip
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Division of Cardiology, Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins Medical Institutions, Baltimore, Maryland.
JAMA. 2016 Nov 22;316(20):2126-2134. doi: 10.1001/jama.2016.17020.
The role of coronary artery calcium (CAC) testing for guiding preventive strategies among women at low cardiovascular disease (CVD) risk based on the American College of Cardiology and American Heart Association CVD prevention guidelines is unclear.
To assess the potential utility of CAC testing for CVD risk estimation and stratification among low-risk women.
DESIGN, SETTING, AND PARTICIPANTS: Women with 10-year atherosclerotic CVD (ASCVD) risk lower than 7.5% from 5 large population-based cohorts: the Dallas Heart Study (United States), the Framingham Heart Study (United States), the Heinz Nixdorf Recall study (Germany), the Multi-Ethnic Study of Atherosclerosis (United States), and the Rotterdam Study (the Netherlands). The 5 cohorts were selected based on the availability of CAC data in a sizable group of low-risk women from the general population together with the long detailed follow-up data. Across the cohorts, events were assessed from the date of CAC scan (performed from 1998 through 2006) until January 1, 2012; January 1, 2014; or March 6, 2015. Fixed-effects meta-analysis was conducted to combine the results of the 5 studies.
CAC score by computed tomography.
Main outcome was incident ASCVD, including nonfatal myocardial infarction, coronary heart disease (CHD) death, and stroke. Association of CAC with ASCVD was examined using Cox proportional hazards models. To assess whether CAC was associated with improved ASCVD risk predictions beyond the traditional risk factors, the C statistic and the continuous net reclassification improvement (cNRI) index were calculated.
Among 6739 women with low ASCVD risk from the 5 studies, mean age ranged from 44 to 63 years and CAC was present in 36.1%. Across the cohorts, median follow-up ranged from 7.0 to 11.6 years. A total of 165 ASCVD events occurred (64 nonfatal myocardial infarctions, 29 CHD deaths, and 72 strokes), with the ASCVD incidence rates ranging from 1.5 to 6.0 per 1000 person-years. Compared with the absence of CAC (CAC = 0), presence of CAC (CAC >0) was associated with an increased risk of ASCVD (incidence rates per 1000 person-years, 1.41 for CAC absence vs 4.33 for CAC presence; difference, 2.92 [95% CI, 2.02-3.83]; multivariable-adjusted hazard ratio, 2.04 [95% CI, 1.44-2.90]). The addition of CAC to traditional risk factors improved the C statistic from 0.73 (95% CI, 0.69-0.77) to 0.77 (95% CI, 0.74-0.81) and provided a cNRI of 0.20 (95% CI, 0.09-0.31) for ASCVD prediction.
Among women at low ASCVD risk, CAC was present in approximately one-third and was associated with an increased risk of ASCVD and modest improvement in prognostic accuracy compared with traditional risk factors. Further research is needed to assess the clinical utility and cost-effectiveness of this additional accuracy.
根据美国心脏病学会和美国心脏协会的心血管疾病(CVD)预防指南,冠状动脉钙化(CAC)检测在指导低心血管疾病风险女性的预防策略中的作用尚不清楚。
评估CAC检测在低风险女性心血管疾病风险评估和分层中的潜在效用。
设计、设置和参与者:来自5个大型人群队列中10年动脉粥样硬化性心血管疾病(ASCVD)风险低于7.5%的女性:达拉斯心脏研究(美国)、弗雷明汉心脏研究(美国)、海因茨·尼克斯多夫召回研究(德国)、动脉粥样硬化多族裔研究(美国)和鹿特丹研究(荷兰)。这5个队列是根据普通人群中大量低风险女性的CAC数据可用性以及长期详细随访数据来选择的。在各个队列中,事件评估从CAC扫描日期(1998年至2006年进行)至2012年1月1日、2014年1月1日或2015年3月6日。进行固定效应荟萃分析以合并5项研究的结果。
计算机断层扫描的CAC评分。
主要结局是发生ASCVD,包括非致命性心肌梗死、冠心病(CHD)死亡和中风。使用Cox比例风险模型检查CAC与ASCVD的关联。为了评估除传统危险因素外,CAC是否与改善的ASCVD风险预测相关,计算了C统计量和连续净重新分类改善(cNRI)指数。
在5项研究中的6739名低ASCVD风险女性中,平均年龄在44至63岁之间,36.1%存在CAC。在各个队列中,中位随访时间为7.0至11.6年。共发生165例ASCVD事件(64例非致命性心肌梗死、29例CHD死亡和72例中风),ASCVD发病率为每1000人年1.5至6.0例。与无CAC(CAC = 0)相比,存在CAC(CAC>0)与ASCVD风险增加相关(每1000人年发病率,无CAC为1.41,有CAC为4.33;差异为2.92 [95% CI,2.02 - 3.83];多变量调整风险比为2.04 [95% CI,1.44 - 2.90])。将CAC添加到传统危险因素中可使C统计量从0.73(95% CI,0.69 - 0.77)提高到0.77(95% CI,0.74 - 0.81),并为ASCVD预测提供了0.20(95% CI,0.09 - 0.31)的cNRI。
在低ASCVD风险女性中,约三分之一存在CAC,与ASCVD风险增加相关,并且与传统危险因素相比,预后准确性有适度改善。需要进一步研究来评估这种额外准确性的临床效用和成本效益。